ArticleCurrent neuropharmacology2011
Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.
Article in Current neuropharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Azathioprine for people with multiple sclerosis.The Cochrane database of systematic reviews · 2024Pooled it
- Review
- Bibliometric and visual analysis of overlooked fatigue in kidney transplantation: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Article
- Identification of potential drug-induced neuralgia signals through disproportionality analysis of the FAERS database.Frontiers in pharmacology · 2025Article
- CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy.Frontiers in immunology · 2025Review
- Testicular immunity.Molecular aspects of medicine · 2024Review
- Chemoproteomic development of SLC15A4 inhibitors with anti-inflammatory activity.Nature chemical biology · 2024Article
- Review
- Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept.Immune network · 2022Review
- The Kv1.3 KBiologia futura · 2021Review
- Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation.Frontiers in immunology · 2020Article
- ImmunoSPdb: an archive of immunosuppressive peptides.Database : the journal of biological databases and curation · 2019Article
- Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report.BMC pulmonary medicine · 2018Article
- Biomimetic Targeting of Nanoparticles to Immune Cell Subsets via Cognate Antigen Interactions.Molecular pharmaceutics · 2018Article
- Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis.Muscle & nerve · 2018Article
- Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Advantages of Structure-Based Drug Design Approaches in Neurological Disorders.Current neuropharmacology · 2017Review
- Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.Drug safety · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In parallel to our better understanding of the role of the immune system in neurologic diseases, there has been an increased availability in therapeutic options for autoimmune neurologic diseases such as multiple sclerosis, myasthenia gravis, polyneuropathies, central nervous system vasculitides and neurosarcoidosis. In many cases, the purported benefits of this class of therapy are anecdotal and not the result of good controlled clinical trials. Nonetheless, their potential efficacy is better known than their adverse event profile. A rationale therapeutic decision by the clinician will depend on a comprehensive understanding of the ratio between efficacy and toxicity. In this review, we outline the most commonly used immune suppressive medications in neurologic disease: cytotoxic chemotherapy, nucleoside analogues, calcineurin inhibitors, monoclonal antibodies and miscellaneous immune suppressants. A discussion of their mechanisms of action and related toxicity is highlighted, with the goal that the reader will be able to recognize the most commonly associated toxicities and identify strategies to prevent and manage problems that are expected to arise with their use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.